Pituitary adenomas and oral contraceptives: A multicenter case-control study

L. Gordis, Ellen B Gold, C. Libauer

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

A case-control study was conducted to determine whether use of oral contraceptives (OCs) is associated with an increased risk of prolactin-secreting pituitary adenomas. Two hundred twelve women with such adenomas (140 of which were surgically confirmed) were recruited from four clinical centers and interviewed and matched by age and race to neighborhood control subjects. In addition, 119 hyperprolactinemic patients with amenorrhea and/or galactorrhea (A/G) who had normal or equivocal tomograms and 205 normoprolactinemic women with A/G were also interviewed and matched to neighborhood control subjects. No increase in relative odds (RO) for any of these groups of patients was found for use of OCs (pituitary adenoma cases versus controls RO = 1.33, 95% confidence intervals [CI = 0.81 to 2.22: equivocal cases versus controls RO = 1.35, 95% CI = 0.69 to 2.70; secondary A/G cases versus controls RO = 0.67, 95% CI = 0.37 to 1.18). History of infertility (RO = 25.5, 95% CI = 8.49 to 76.6), of menstrual problems or A/G (RO = 4.47, 95% CI = 2.21 to 9.05), and of nulliparity (RO = 4.36, 95% CI = 2.10 to 9.04) were each associated with a significantly increased risk of pituitary adenomas. The results of this study do not indicate any increase in risk of pituitary adenomas as a result of using OCs.

Original languageEnglish (US)
Pages (from-to)753-760
Number of pages8
JournalFertility and Sterility
Volume39
Issue number6
StatePublished - 1983

Fingerprint

Pituitary Neoplasms
Oral Contraceptives
Case-Control Studies
Galactorrhea
Odds Ratio
Amenorrhea
Prolactinoma
Parity
Adenoma
Infertility
Confidence Intervals

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Pituitary adenomas and oral contraceptives : A multicenter case-control study. / Gordis, L.; Gold, Ellen B; Libauer, C.

In: Fertility and Sterility, Vol. 39, No. 6, 1983, p. 753-760.

Research output: Contribution to journalArticle

@article{c16c54d79baa4bc991ae6d4a613a65d3,
title = "Pituitary adenomas and oral contraceptives: A multicenter case-control study",
abstract = "A case-control study was conducted to determine whether use of oral contraceptives (OCs) is associated with an increased risk of prolactin-secreting pituitary adenomas. Two hundred twelve women with such adenomas (140 of which were surgically confirmed) were recruited from four clinical centers and interviewed and matched by age and race to neighborhood control subjects. In addition, 119 hyperprolactinemic patients with amenorrhea and/or galactorrhea (A/G) who had normal or equivocal tomograms and 205 normoprolactinemic women with A/G were also interviewed and matched to neighborhood control subjects. No increase in relative odds (RO) for any of these groups of patients was found for use of OCs (pituitary adenoma cases versus controls RO = 1.33, 95{\%} confidence intervals [CI = 0.81 to 2.22: equivocal cases versus controls RO = 1.35, 95{\%} CI = 0.69 to 2.70; secondary A/G cases versus controls RO = 0.67, 95{\%} CI = 0.37 to 1.18). History of infertility (RO = 25.5, 95{\%} CI = 8.49 to 76.6), of menstrual problems or A/G (RO = 4.47, 95{\%} CI = 2.21 to 9.05), and of nulliparity (RO = 4.36, 95{\%} CI = 2.10 to 9.04) were each associated with a significantly increased risk of pituitary adenomas. The results of this study do not indicate any increase in risk of pituitary adenomas as a result of using OCs.",
author = "L. Gordis and Gold, {Ellen B} and C. Libauer",
year = "1983",
language = "English (US)",
volume = "39",
pages = "753--760",
journal = "Fertility and Sterility",
issn = "0015-0282",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Pituitary adenomas and oral contraceptives

T2 - A multicenter case-control study

AU - Gordis, L.

AU - Gold, Ellen B

AU - Libauer, C.

PY - 1983

Y1 - 1983

N2 - A case-control study was conducted to determine whether use of oral contraceptives (OCs) is associated with an increased risk of prolactin-secreting pituitary adenomas. Two hundred twelve women with such adenomas (140 of which were surgically confirmed) were recruited from four clinical centers and interviewed and matched by age and race to neighborhood control subjects. In addition, 119 hyperprolactinemic patients with amenorrhea and/or galactorrhea (A/G) who had normal or equivocal tomograms and 205 normoprolactinemic women with A/G were also interviewed and matched to neighborhood control subjects. No increase in relative odds (RO) for any of these groups of patients was found for use of OCs (pituitary adenoma cases versus controls RO = 1.33, 95% confidence intervals [CI = 0.81 to 2.22: equivocal cases versus controls RO = 1.35, 95% CI = 0.69 to 2.70; secondary A/G cases versus controls RO = 0.67, 95% CI = 0.37 to 1.18). History of infertility (RO = 25.5, 95% CI = 8.49 to 76.6), of menstrual problems or A/G (RO = 4.47, 95% CI = 2.21 to 9.05), and of nulliparity (RO = 4.36, 95% CI = 2.10 to 9.04) were each associated with a significantly increased risk of pituitary adenomas. The results of this study do not indicate any increase in risk of pituitary adenomas as a result of using OCs.

AB - A case-control study was conducted to determine whether use of oral contraceptives (OCs) is associated with an increased risk of prolactin-secreting pituitary adenomas. Two hundred twelve women with such adenomas (140 of which were surgically confirmed) were recruited from four clinical centers and interviewed and matched by age and race to neighborhood control subjects. In addition, 119 hyperprolactinemic patients with amenorrhea and/or galactorrhea (A/G) who had normal or equivocal tomograms and 205 normoprolactinemic women with A/G were also interviewed and matched to neighborhood control subjects. No increase in relative odds (RO) for any of these groups of patients was found for use of OCs (pituitary adenoma cases versus controls RO = 1.33, 95% confidence intervals [CI = 0.81 to 2.22: equivocal cases versus controls RO = 1.35, 95% CI = 0.69 to 2.70; secondary A/G cases versus controls RO = 0.67, 95% CI = 0.37 to 1.18). History of infertility (RO = 25.5, 95% CI = 8.49 to 76.6), of menstrual problems or A/G (RO = 4.47, 95% CI = 2.21 to 9.05), and of nulliparity (RO = 4.36, 95% CI = 2.10 to 9.04) were each associated with a significantly increased risk of pituitary adenomas. The results of this study do not indicate any increase in risk of pituitary adenomas as a result of using OCs.

UR - http://www.scopus.com/inward/record.url?scp=0020604056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020604056&partnerID=8YFLogxK

M3 - Article

C2 - 6682810

AN - SCOPUS:0020604056

VL - 39

SP - 753

EP - 760

JO - Fertility and Sterility

JF - Fertility and Sterility

SN - 0015-0282

IS - 6

ER -